HomepageABVX • EPA
add
Abivax SA
Vorige slotkoers
€ 102,00
Dag-range
€ 96,00 - € 103,80
Jaar-range
€ 4,51 - € 132,00
Beurswaarde
8,15Â mld. EUR
Gem. volume
234,43K
Koers/winst
-
Dividendrendement
-
Primaire beurs
EPA
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (EUR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,91Â mln. | -55,37% |
Bedrijfskosten | 73,56Â mln. | 50,47% |
Netto inkomsten | -81,96Â mln. | -108,14% |
Netto winstmarge | -4,28K | -366,40% |
Winst per aandeel | — | — |
EBITDA | -70,76Â mln. | -61,81% |
Effectief belastingtarief | -7,68% | — |
Balans
Totale activa
Totale passiva
| (EUR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 530,38Â mln. | 267,41% |
Totale activa | 584,34Â mln. | 184,73% |
Totale passiva | 129,14Â mln. | -21,57% |
Totaal aandelenvermogen | 455,20 mln. | — |
Uitstaande aandelen | 79,19 mln. | — |
Koers-boekwaardeverhouding | 17,59 | — |
Rendement op activa | -28,97% | — |
Rendement op kapitaal | -33,40% | — |
Kasstroom
Nettomutatie in liquide middelen
| (EUR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -81,96Â mln. | -108,14% |
Operationele kasstroom | -23,23Â mln. | 30,69% |
Kasstroom uit beleggingen | -12,74Â mln. | -2.391,73% |
Kasstroom uit financiering | -39,55Â mln. | -578,85% |
Nettomutatie in liquide middelen | -73,02Â mln. | -101,54% |
Vrije kasstroom | -20,15 mln. | — |
Over
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Opgericht
4 dec 2013
Website
Werknemers
69
